ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Anti-psoriatic potential of nanocarrier formulated with Deverra tortuosa DC. and Deverra triradiata hochst aerial extracts: in vivo evaluation in mice.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic autoimmune skin disorder marked by rapid skin cell proliferation, causing red, scaly patches. Current treatments often show limited efficacy and adverse effects. The family Apiaceae is traditionally valued for its medicinal uses, particularly anti-inflammatory effects, and among its members are Deverra tortuosa (Desf.) DC. (D. tortuosa) and Deverra triradiata Hochst. ex Bioss. (D. triradiata) with recognized therapeutic value. As nanotechnology-based formulations enhance skin penetration and therapeutic efficacy, this study investigated the antipsoriatic activity of plant-based nanocreams (NCs). Phenolic content of D. tortuosa and D. triradiata aerial parts was analyzed by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Nanoparticles were prepared with droplet sizes of 300-470 nm and a positive surface charge. Mice were divided into five groups: control (cream base), imiquimod (IMQU; 62.5 mg/day for 7 days), a commonly used inducer of psoriasis-like dermatitis, standard (tacrolimus 20 mg/kg/day, 2 h after IMQU), IMQU + D. triradiata NC (2% once daily, 2 h after IMQU), and IMQU + D. tortuosa NC (2% once daily, 2 h after IMQU). D. tortuosa and D. triradiata NCs significantly alleviated IMQU-induced systemic and skin-related psoriatic changes in mice by reducing spleen index, inflammatory cytokines, including interleukin-17 (IL-17), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as nuclear factor kappa-B (NF-κB), signal transducer and activator of transcription-3 (STAT3), and Ki-67 expression. Histological analysis confirmed marked restoration of normal skin architecture, with D. tortuosa showing the highest therapeutic efficacy. These findings suggest that D. tortuosa and D. triradiata NCs possess promising anti-psoriatic potential, through immunomodulatory and anti-inflammatory mechanisms, with D. tortuosa demonstrating superior efficacy. They may serve as effective natural alternatives to conventional psoriasis treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.